Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 1152Prostatic Neoplasms 642Neoplasms 581Carcinoma, Non-Small-Cell Lung 488Multiple Myeloma 483Leukemia, Myeloid, Acute 461Leukemia 418Lung Neoplasms 399Lymphoma 381Leukemia, Lymphocytic, Chronic, B-Cell 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Lymphoma, Non-Hodgkin 326Colorectal Neoplasms 310Pancreatic Neoplasms 306Neoplasm Metastasis 302Myelodysplastic Syndromes 301Melanoma 286Hodgkin Disease 253Head and Neck Neoplasms 249Brain Neoplasms 231Lymphoma, Follicular 224Ovarian Neoplasms 221Recurrence 220Glioblastoma 215Lymphoma, Mantle-Cell 211Lymphoma, Large B-Cell, Diffuse 209Squamous Cell Carcinoma of Head and Neck 176Colonic Neoplasms 162Carcinoma, Renal Cell 158Carcinoma, Hepatocellular 154

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × Hormone Refractory Prostate Cancer × Clear all
NCT00928252 2017-08-14

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Queen's Medical Center

Phase 1/2 Completed
25 enrolled 9 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00629525 2015-03-03

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Duke University

Phase 2 Completed
35 enrolled 6 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00906243 2012-04-04

RNActive®-Derived Therapeutic Vaccine

University of Florida

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡